- World Pharma News Home » Clinical Trials » Bayer's Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome
(a free service delivered by FeedBurner)
Findings from the ATLAS ACS TIMI 46 study - a Phase II study of the novel oral anticoagulant Xarelto® (rivaroxaban) - were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008 in New Orleans by C. Michael Gibson, M.D., Director of the TIMI Data Coordinating Center, Harvard Medical School, Boston, Massachusetts, USA. Results from this Phase II study support moving rivaroxaban into a pivotal Phase III trial for the secondary prevention of acute coronary syndrome (ACS) later this year.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments